Neuralink receives FDA approval to implant brain chip in second patient

Elon Musk’s Neuralink has received approval from the Food and Drug Administration(FDA) to implant its experimental brain chip Telepathy in a second patient.

Neuralink, the brain-chip startup founded by Elon Musk, has been given the green light by the FDA to proceed with implanting a brain chip in a second patient. This decision follows complications encountered with the first trial participant To address these issues, Neuralink has made adjustments, including embedding some of the device’s ultrathin wires deeper into the brain, according to a source familiar with the company and a document reviewed by the Wall Street Journal.

Neuralink plans to expand the trial to include 10 participants this year, enabling them to interact with computers using their thoughts. The primary goal of the project, known as the PRIME Study, is to develop a “fully implantable, wireless brain-computer interface” that allows users to control a computer cursor or keyboard with their thoughts.

This groundbreaking technology reportedly has the potential to offer transformative treatments for physical disabilities, such as blindness and paralysis, as well as conditions, like autism, depression, obesity and schizophrenia.